Skip to main content

Articles

Page 1 of 103

  1. Breast cancer and its therapies frequently result in significant musculoskeletal morbidity. Skeletal complications include bone metastases, pain, bone loss, osteoporosis, and fracture. In addition, muscle loss...

    Authors: Tarah J. Ballinger, William R. Thompson and Theresa A. Guise
    Citation: Breast Cancer Research 2022 24:84
  2. Intraoperative electron radiotherapy (IOERT) can be used to treat early breast cancer during the conservative surgery thus enabling shorter overall treatment times and reduced irradiation of organs at risk. We...

    Authors: Catherine Philippson, Samuel Larsen, Stéphane Simon, Christophe Vandekerkhove, Alex De Caluwe, Dirk Van Gestel, Marie Chintinne, Isabelle Veys, Filip De Neubourg, Danièle Noterman, Mirela Roman, Jean-Marie Nogaret and Antoine Desmet
    Citation: Breast Cancer Research 2022 24:83
  3. Authors: Daniele Giardiello, Maartje J. Hooning, Michael Hauptmann, Renske Keeman, B. A. M. Heemskerk-Gerritsen, Heiko Becher, Carl Blomqvist, Stig E. Bojesen, Manjeet K. Bolla, Nicola J. Camp, Kamila Czene, Peter Devilee, Diana M. Eccles, Peter A. Fasching, Jonine D. Figueroa, Henrik Flyger…
    Citation: Breast Cancer Research 2022 24:82

    The original article was published in Breast Cancer Research 2022 24:69

  4. The biological phenotype of tumours evolves during neoadjuvant chemotherapy (NAC). Accurate prediction of pathological complete response (pCR) to NAC in the early-stage or posttreatment can optimize treatment ...

    Authors: Lei Wu, Weitao Ye, Yu Liu, Dong Chen, Yuxiang Wang, Yanfen Cui, Zhenhui Li, Pinxiong Li, Zhen Li, Zaiyi Liu, Min Liu, Changhong Liang, Xiaotang Yang, Yu Xie and Ying Wang
    Citation: Breast Cancer Research 2022 24:81
  5. The vast majority of research studies that have described the links between DNA damage repair or homologous recombination deficiency (HRD) score, and tumor biology, have concerned either triple negative breast...

    Authors: Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, François Ghiringhelli, Caroline Truntzer and Sylvain Ladoire
    Citation: Breast Cancer Research 2022 24:80
  6. Breast tumor immune infiltration is clearly associated with improved treatment response and outcomes in breast cancer. However, modifiable patient factors associated with breast cancer immune infiltrates are p...

    Authors: Sarah Asad, Adrienne Damicis, Yujing J. Heng, Kathryn Kananen, Katharine A. Collier, Elizabeth J. Adams, Kevin H. Kensler, Gabrielle M. Baker, Robert Wesolowski, Sagar Sardesai, Margaret Gatti-Mays, Bhuvaneswari Ramaswamy, A. Heather Eliassen, Susan E. Hankinson, Fred K. Tabung, Rulla M. Tamimi…
    Citation: Breast Cancer Research 2022 24:78
  7. Associations of birthweight, childhood body size and pubertal timing with breast cancer risks by menopausal status and tumor receptor subtypes are inconclusive. Thus, we investigated these associations in a po...

    Authors: Dorthe C. Pedersen, Britt W. Jensen, Anne Tjønneland, Zorana J. Andersen, Lene Mellemkjaer, Lise G. Bjerregaard, Julie Aarestrup and Jennifer L. Baker
    Citation: Breast Cancer Research 2022 24:77
  8. Breast parenchymal texture features, including grayscale variation (V), capture the patterns of texture variation on a mammogram and are associated with breast cancer risk, independent of mammographic density ...

    Authors: Yuxi Liu, Hongjie Chen, John Heine, Sara Lindstrom, Constance Turman, Erica T. Warner, Stacey J. Winham, Celine M. Vachon, Rulla M. Tamimi, Peter Kraft and Xia Jiang
    Citation: Breast Cancer Research 2022 24:76
  9. Breast cancer is a heterogenous disease with several histological and molecular subtypes. Models that represent these subtypes are essential for translational research aimed at improving clinical strategy for ...

    Authors: Ludmila Szabova, Melanie B. Gordon, Lucy Lu, Nathan Pate, Laura Bassel, Anthony J. Iacovelli, Baktiar Karim, Philip J. Homan, Deborah B. Householder, Theresa M. Guerin, Sandra Burkett, Amanda M. Day, Wendi Custer and Zoe Weaver Ohler
    Citation: Breast Cancer Research 2022 24:75
  10. The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx Breast R...

    Authors: Michael Crager, Sameera R. Wijayawardana, Aaron M. Gruver, Andrea Blacklock, Christy Russell, Frederick L. Baehner and Francisco Sapunar
    Citation: Breast Cancer Research 2022 24:74
  11. The tumor immune microenvironment (TIME) generated by cancer-infiltrating immune cells has a crucial role in promoting or suppressing breast cancer progression. However, whether the steroid receptor coactivato...

    Authors: Sang Jun Han, Nuri Sung, Jin Wang, Bert W. O’Malley and David M. Lonard
    Citation: Breast Cancer Research 2022 24:73
  12. Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses on prolonging patients’ (pts) overall survival (OS) and improving their quality of life. Eribulin is a microtubule inhibitor tha...

    Authors: Nicla La Verde, Giovanna Damia, Ornella Garrone, Daniele Santini, Alessandra Fabi, Mariangela Ciccarese, Daniele Giulio Generali, Martina Nunzi, Elena Poletto, Elisa Ferraris, Elisabetta Cretella, Giuseppa Scandurra, Icro Meattini, Alessandro Stefano Bertolini, Luigi Cavanna, Elena Collovà…
    Citation: Breast Cancer Research 2022 24:71
  13. Metastatic breast carcinoma is commonly considered during differential diagnosis when metastatic disease is detected in females. In addition to the tumor morphology and documented clinical history, sensitive a...

    Authors: Tian Du, Lu Pan, Chengyou Zheng, Keming Chen, Yuanzhong Yang, Jiewei Chen, Xue Chao, Mei Li, Jiabin Lu, Rongzhen Luo, Jinhui Zhang, Yu Wu, Jiehua He, Dongping Jiang and Peng Sun
    Citation: Breast Cancer Research 2022 24:70
  14. Prediction of contralateral breast cancer (CBC) risk is challenging due to moderate performances of the known risk factors. We aimed to improve our previous risk prediction model (PredictCBC) by updated follow...

    Authors: Daniele Giardiello, Maartje J. Hooning, Michael Hauptmann, Renske Keeman, B. A. M. Heemskerk-Gerritsen, Heiko Becher, Carl Blomqvist, Stig E. Bojesen, Manjeet K. Bolla, Nicola J. Camp, Kamila Czene, Peter Devilee, Diana M. Eccles, Peter A. Fasching, Jonine D. Figueroa, Henrik Flyger…
    Citation: Breast Cancer Research 2022 24:69
  15. Ductal carcinoma in situ (DCIS) is the most common type of in situ premalignant breast cancers. What drives DCIS to invasive breast cancer is unclear. Basal-like invasive breast cancers are aggressive. We have...

    Authors: Ze-Yi Zheng, Hanan Elsarraj, Jonathan T. Lei, Yan Hong, Meenakshi Anurag, Long Feng, Hilda Kennedy, Yichao Shen, Flora Lo, Zifan Zhao, Bing Zhang, Xiang H.-F. Zhang, Ossama W. Tawfik, Fariba Behbod and Eric C. Chang
    Citation: Breast Cancer Research 2022 24:68
  16. Rating lymphocytes (TILs) are a prognostic marker in breast cancer and high TIL infiltration correlates with better patient outcomes. Meanwhile, parameters involving immune cells in peripheral blood have also ...

    Authors: Hiroko Onagi, Yoshiya Horimoto, Asumi Sakaguchi, Daiki Ikarashi, Naotake Yanagisawa, Takayuki Nakayama, Tetsuya Nakatsura, Yumiko Ishizuka, Ritsuko Sasaki, Junichiro Watanabe, Mitsue Saito, Harumi Saeki, Takuo Hayashi, Atsushi Arakawa, Takashi Yao and Shigehisa Kitano
    Citation: Breast Cancer Research 2022 24:67
  17. Breast cancer (BC) has the highest cancer incidence and mortality in women worldwide. Observational epidemiological studies suggest a positive association between testosterone, estradiol, dehydroepiandrosteron...

    Authors: Aayah Nounu, Siddhartha P. Kar, Caroline L. Relton and Rebecca C. Richmond
    Citation: Breast Cancer Research 2022 24:66
  18. Ribosomal biogenesis and ribosomal proteins have attracted attention in the context of tumor biology in recent years. Instead of being mere translational machineries, ribosomes might play an active role in tum...

    Authors: Anne-Marie Lüchtenborg, Patrick Metzger, Miguel Cosenza Contreras, Victor Oria, Martin L. Biniossek, Franziska Lindner, Klemens Fröhlich, Ambrus Malyi, Thalia Erbes, Nicole Gensch, Jochen Maurer, Andreas Thomsen, Melanie Boerries, Oliver Schilling, Martin Werner and Peter Bronsert
    Citation: Breast Cancer Research 2022 24:65
  19. Papillomas of the breast pose challenges for treatment decisions as their risk for transformation to breast cancer is low but not negligible. To spare low-risk patients the burden of substantial treatment side...

    Authors: Piotr Ziółkowski, Marta Woźniak, Ahmad Mansour, Yu An and Georg F. Weber
    Citation: Breast Cancer Research 2022 24:64
  20. Breast cancer cell lines (BCCLs) and patient-derived xenografts (PDXs) are the most frequently used models in breast cancer research. Despite their widespread usage, genome sequencing of these models is incomp...

    Authors: Niantao Deng, Andre Minoche, Kate Harvey, Meng Li, Juliane Winkler, Andrei Goga and Alex Swarbrick
    Citation: Breast Cancer Research 2022 24:63
  21. Current clinical criteria do not discriminate well between women who will or those who will not develop ipsilateral invasive breast cancer (IBC), or a DCIS recurrence after a ductal carcinoma in situ (DCIS) di...

    Authors: Olivier Loudig, Megan I. Mitchell, Iddo Z. Ben-Dov, Christina Liu and Susan Fineberg
    Citation: Breast Cancer Research 2022 24:62
  22. In clinical practice, oestrogen receptor (ER) analysis is almost entirely by immunohistochemistry (IHC). ASCO/CAP recommends cut-offs of < 1% (negative) and 1–10% (low) cells positive. There is uncertainty whe...

    Authors: Elena Lopez-Knowles, Simone Detre, Margaret Hills, Eugene F. Schuster, Maggie C. U. Cheang, Holly Tovey, Lucy S. Kilburn, Judith M. Bliss, John Robertson, Elizabeth Mallon, Anthony Skene, Abigail Evans, Ian Smith and Mitch Dowsett
    Citation: Breast Cancer Research 2022 24:61
  23. Patients with triple-negative breast cancer (TNBC) often have poorer prognosis than those with other subtypes because of its aggressive behaviors. Cancer cells are heterogeneous, and only a few highly metastat...

    Authors: Chunning Li, Teizo Yoshimura, Miao Tian, Yuze Wang, Takamasa Kondo, Ken-Ichi Yamamoto, Masayoshi Fujisawa, Toshiaki Ohara, Masakiyo Sakaguchi and Akihiro Matsukawa
    Citation: Breast Cancer Research 2022 24:60
  24. DNA methylation in blood may reflect adverse exposures accumulated over the lifetime and could therefore provide potential improvements in the prediction of cancer risk. A substantial body of research has show...

    Authors: Pierre-Antoine Dugué, Clara Bodelon, Felicia F. Chung, Hannah R. Brewer, Srikant Ambatipudi, Joshua N. Sampson, Cyrille Cuenin, Veronique Chajès, Isabelle Romieu, Giovanni Fiorito, Carlotta Sacerdote, Vittorio Krogh, Salvatore Panico, Rosario Tumino, Paolo Vineis, Silvia Polidoro…
    Citation: Breast Cancer Research 2022 24:59
  25. Higher density of stromal tumor-infiltrating lymphocytes (sTILs) at baseline has been associated with increased rates of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in triple-neg...

    Authors: Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, Matthias Christgen, Ronald Kates, Eva Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Sherko Kuemmel, Rachel Wuerstlein, Monika Graeser…
    Citation: Breast Cancer Research 2022 24:58
  26. Predictive biomarkers are needed to identify oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER + /HER2-) metastatic breast cancer (MBC) patients who would likely benefit from c...

    Authors: Cheng Liu, Shihui Hu, Xiaoping Xu, Yongping Zhang, Biyun Wang, Shaoli Song and Zhongyi Yang
    Citation: Breast Cancer Research 2022 24:57
  27. Breast cancer (BCa) has long been a health burden to women across the globe. However, the burden is not equally carried across races. Though the manifestation and behavior of BCa differs among racial groups, t...

    Authors: Shannique Clarke, Sheray N. Chin, Leah Dodds, Sophia H. L. George and Simone Badal
    Citation: Breast Cancer Research 2022 24:56
  28. Abbreviated breast MRI (abMRI) is being introduced in breast screening trials and clinical practice, particularly for women with dense breasts. Upscaling abMRI provision requires the workforce of mammogram rea...

    Authors: Lyn I. Jones, Andrea Marshall, Premkumar Elangovan, Rebecca Geach, Sadie McKeown-Keegan, Sarah Vinnicombe, Sam A. Harding, Sian Taylor-Phillips, Mark Halling-Brown, Christopher Foy, Elizabeth O’Flynn, Hesam Ghiasvand, Claire Hulme and Janet A. Dunn
    Citation: Breast Cancer Research 2022 24:55
  29. Invasive lobular breast carcinoma (ILC), the second most prevalent histological subtype of breast cancer, exhibits unique molecular features compared with the more common invasive ductal carcinoma (IDC). While...

    Authors: Sanghoon Lee and Hatice Ulku Osmanbeyoglu
    Citation: Breast Cancer Research 2022 24:54
  30. Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistanc...

    Authors: Annamaria Salvati, Viola Melone, Assunta Sellitto, Francesca Rizzo, Roberta Tarallo, Tuula A. Nyman, Giorgio Giurato, Giovanni Nassa and Alessandro Weisz
    Citation: Breast Cancer Research 2022 24:52
  31. Deregulated signaling pathways are a hallmark feature of oncogenesis and driver of tumor progression. Dual specificity protein phosphatase 4 (DUSP4) is a critical negative regulator of the mitogen-activated pr...

    Authors: Ann Hanna, Mellissa J. Nixon, M. Valeria Estrada, Violeta Sanchez, Quanhu Sheng, Susan R. Opalenik, Abigail L. Toren, Joshua Bauer, Phillip Owens, Frank M. Mason, Rebecca S. Cook, Melinda E. Sanders, Carlos L. Arteaga and Justin M. Balko
    Citation: Breast Cancer Research 2022 24:51
  32. Authors: Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes and Sherene Loi
    Citation: Breast Cancer Research 2022 24:50

    The original article was published in Breast Cancer Research 2020 22:91

  33. Early age at menarche and tall stature are associated with increased breast cancer risk. We examined whether these associations were also positively associated with mammographic density, a strong marker of bre...

    Authors: Sarah V. Ward, Anya Burton, Rulla M. Tamimi, Ana Pereira, Maria Luisa Garmendia, Marina Pollan, Norman Boyd, Isabel dos-Santos-Silva, Gertraud Maskarinec, Beatriz Perez-Gomez, Celine Vachon, Hui Miao, Martín Lajous, Ruy López-Ridaura, Kimberly Bertrand, Ava Kwong…
    Citation: Breast Cancer Research 2022 24:49
  34. A pro-oxidant enzyme, NADPH oxidase 4 (Nox4) has been reported to be a critical downstream effector of TGFβ-induced myofibroblast transformation during fibrosis. While there are a small number of studies sugge...

    Authors: Shakeel Mir, Briana D. Ormsbee Golden, Brandon J. Griess, Raghupathy Vengoji, Eric Tom, Elizabeth A. Kosmacek, Rebecca E. Oberley-Deegan, Geoffrey A. Talmon, Vimla Band and Melissa LT. Teoh-Fitzgerald
    Citation: Breast Cancer Research 2022 24:48
  35. Polycyclic aromatic hydrocarbons (PAH), which are found in air pollution, have carcinogenic and endocrine disrupting properties that might increase breast cancer risk. PAH exposure might be particularly detrim...

    Authors: Rebecca D. Kehm, E. Jane Walter, Sabine Oskar, Melissa L. White, Parisa Tehranifar, Julie B. Herbstman, Frederica Perera, Lothar Lilge, Rachel L. Miller and Mary Beth Terry
    Citation: Breast Cancer Research 2022 24:47
  36. Locally advanced breast cancer (LABC), the most aggressive form of the disease, is a serious threat for women's health worldwide. The AU-rich RNA-binding factor 1 (AUF1) promotes the formation of chemo-resista...

    Authors: Taher Al-Tweigeri, Noura N. AlRaouji, Asma Tulbah, Maria Arafah, Mouad Aboussekhra, Falah Al-Mohanna, Ahmed Mostafa Gad, Abdelmonneim M. Eldali, Tusneem A. Elhassan and Abdelilah Aboussekhra
    Citation: Breast Cancer Research 2022 24:46
  37. Breast terminal duct lobular units (TDLUs), the source of most breast cancer (BC) precursors, are shaped by age-related involution, a gradual process, and postpartum involution (PPI), a dramatic inflammatory p...

    Authors: Joshua Ogony, Thomas de Bel, Derek C. Radisky, Jennifer Kachergus, E. Aubrey Thompson, Amy C. Degnim, Kathryn J. Ruddy, Tracy Hilton, Melody Stallings-Mann, Celine Vachon, Tanya L. Hoskin, Michael G. Heckman, Robert A. Vierkant, Launia J. White, Raymond M. Moore, Jodi Carter…
    Citation: Breast Cancer Research 2022 24:45
  38. Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit from the ...

    Authors: Christine Aaserød Pedersen, Maria Dung Cao, Thomas Fleischer, Morten B. Rye, Stian Knappskog, Hans Petter Eikesdal, Per Eystein Lønning, Jörg Tost, Vessela N. Kristensen, May-Britt Tessem, Guro F. Giskeødegård and Tone F. Bathen
    Citation: Breast Cancer Research 2022 24:43
  39. Obesity and adult weight gain are linked to increased breast cancer risk and poorer clinical outcomes in postmenopausal women, particularly for hormone-dependent tumors. Menopause is a time when significant we...

    Authors: Elizabeth A. Wellberg, Karen A. Corleto, L. Allyson Checkley, Sonali Jindal, Ginger Johnson, Janine A. Higgins, Sarina Obeid, Steven M. Anderson, Ann D. Thor, Pepper J. Schedin, Paul S. MacLean and Erin D. Giles
    Citation: Breast Cancer Research 2022 24:42
  40. The majority of BRCA1-mutant breast cancers are characterized by a triple-negative phenotype and a basal-like molecular subtype, associated with aggressive clinical behavior. Current treatment options are limited...

    Authors: Leonie Ratz, Chiara Brambillasca, Leandra Bartke, Maxim A. Huetzen, Jonas Goergens, Orsolya Leidecker, Ron D. Jachimowicz, Marieke van de Ven, Natalie Proost, Bjørn Siteur, Renske de Korte-Grimmerink, Peter Bouwman, Emilia M. Pulver, Roebi de Bruijn, Jörg Isensee, Tim Hucho…
    Citation: Breast Cancer Research 2022 24:41
  41. The Bcl-3 protein is an atypical member of the inhibitor of -κB family that has dual roles as a transcriptional repressor and a coactivator for dimers of NF-κB p50 and p52. Bcl-3 is expressed in mammary adenoc...

    Authors: David Carr, Aiman Zein, Josée Coulombe, Tianqi Jiang, Miguel A. Cabrita, Gwendoline Ward, Manijeh Daneshmand, Andrea Sau and M. A. Christine Pratt
    Citation: Breast Cancer Research 2022 24:40
  42. Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosupp...

    Authors: Micaela Harrasser, Satyen Harish Gohil, Hiu Lau, Marco Della Peruta, Vincent Muczynski, Dominic Patel, Elena Miranda, Kristiana Grigoriadis, Anita Grigoriadis, David Granger, Rachel Evans and Amit Chunilal Nathwani
    Citation: Breast Cancer Research 2022 24:39
  43. The effect of extracellular microenvironment (hypoxia and pH) has been regarded as a key hallmark in cancer progression. The study aims to investigate the effects of carbonic anhydrase IX (CAIX), a key hypoxia...

    Authors: Chong Hui Clara Ong, Dong Yeul Lee, Bernett Lee, Huihua Li, Jeffrey Chun Tatt Lim, Johnathan Xiande Lim, Joe Poh Sheng Yeong, Hiu Yeung Lau, Aye Aye Thike, Puay Hoon Tan and Jabed Iqbal
    Citation: Breast Cancer Research 2022 24:38
  44. Triple negative breast cancer (TNBC) is an aggressive subtype of invasive breast cancer that disproportionately affects Black women and contributes to racial disparities in breast cancer mortality. Prior resea...

    Authors: Scott D. Siegel, Madeline M. Brooks, Shannon M. Lynch, Jennifer Sims-Mourtada, Zachary T. Schug and Frank C. Curriero
    Citation: Breast Cancer Research 2022 24:37
  45. Up to 60% of breast cancer patients treated with chemotherapy is confronted with cognitive problems, which can have a significant impact on daily activities and quality of life (QoL). We investigated whether e...

    Authors: E. W. Koevoets, S. B. Schagen, M. B. de Ruiter, M. I. Geerlings, L. Witlox, E. van der Wall, M. M. Stuiver, G. S. Sonke, M. J. Velthuis, J. J. Jobsen, M. B. E. Menke-Pluijmers, E. Göker, C. C. van der Pol, M. E. M. M. Bos, L. W. Tick, N. A. van Holsteijn…
    Citation: Breast Cancer Research 2022 24:36
  46. CCR5 is a motility chemokine receptor implicated in tumor progression, whose activation and subsequent endocytosis may identify highly aggressive breast cancer cell subtypes likely to spread into the circulato...

    Authors: Ashvathi Raghavakaimal, Massimo Cristofanilli, Cha-Mei Tang, R. K. Alpaugh, Kirby P. Gardner, Saranya Chumsri and Daniel L. Adams
    Citation: Breast Cancer Research 2022 24:35

Annual Journal Metrics